CL2020000271A1 - Combinación terapéutica de un inhibidor tirosina quinasa del egfr y un inhibidor de quinasa dependiente de ciclina. - Google Patents
Combinación terapéutica de un inhibidor tirosina quinasa del egfr y un inhibidor de quinasa dependiente de ciclina.Info
- Publication number
- CL2020000271A1 CL2020000271A1 CL2020000271A CL2020000271A CL2020000271A1 CL 2020000271 A1 CL2020000271 A1 CL 2020000271A1 CL 2020000271 A CL2020000271 A CL 2020000271A CL 2020000271 A CL2020000271 A CL 2020000271A CL 2020000271 A1 CL2020000271 A1 CL 2020000271A1
- Authority
- CL
- Chile
- Prior art keywords
- kinase inhibitor
- combination
- egfr tyrosine
- cyclin
- cancer
- Prior art date
Links
- 229940126074 CDK kinase inhibitor Drugs 0.000 title 1
- 102100034770 Cyclin-dependent kinase inhibitor 3 Human genes 0.000 title 1
- 101000945639 Homo sapiens Cyclin-dependent kinase inhibitor 3 Proteins 0.000 title 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 title 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 title 1
- 229940121647 egfr inhibitor Drugs 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 3
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 abstract 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- 229940121646 third-generation egfr tyrosine kinase inhibitor Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
ESTA INVENCIÓN ESTÁ RELACIONADA CON UNA COMBINACIÓN FARMACÉUTICA QUE COMPRENDE (A) UN INHIBIDOR DE TIROSINA QUINASA DEL EGFR DE TERCERA GENERACIÓN Y (B) UN INHIBIDOR DE QUINASA DEPENDIENTE DE CICLINA 4/6 (CDK4/6), EN PARTICULAR, PARA USAR EN EL TRATAMIENTO DE UN CÁNCER, EN PARTICULAR, UN CÁNCER DE PULMÓN. ESTA INVENCIÓN TAMBIÉN ESTÁ RELACIONADA CON USOS DE DICHA COMBINACIÓN PARA LA PREPARACIÓN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE UN CÁNCER; MÉTODOS PARA TRATAR UN CÁNCER EN UN SUJETO QUE LOS NECESITA QUE COMPRENDEN ADMINISTRAR A DICHO SUJETO UNA CANTIDAD CONJUNTAMENTE TERAPÉUTICAMENTE EFICAZ DE DICHA COMBINACIÓN; COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN DICHA COMBINACIÓN Y EMPAQUES COMERCIALES PARA ESTAS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762540594P | 2017-08-03 | 2017-08-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020000271A1 true CL2020000271A1 (es) | 2020-08-28 |
Family
ID=63405288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020000271A CL2020000271A1 (es) | 2017-08-03 | 2020-01-30 | Combinación terapéutica de un inhibidor tirosina quinasa del egfr y un inhibidor de quinasa dependiente de ciclina. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20200155566A1 (es) |
| EP (1) | EP3661519A1 (es) |
| JP (1) | JP2020529423A (es) |
| KR (1) | KR20200036879A (es) |
| CN (1) | CN110996962A (es) |
| AU (1) | AU2018311522A1 (es) |
| BR (1) | BR112020001821A2 (es) |
| CA (1) | CA3069561A1 (es) |
| CL (1) | CL2020000271A1 (es) |
| IL (1) | IL272369A (es) |
| JO (1) | JOP20200015A1 (es) |
| MX (1) | MX2020001253A (es) |
| PH (1) | PH12020500099A1 (es) |
| RU (1) | RU2020108191A (es) |
| SG (1) | SG11201913244QA (es) |
| TW (1) | TW201909921A (es) |
| WO (1) | WO2019026006A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3738084A4 (en) | 2018-01-08 | 2021-11-17 | G1 Therapeutics, Inc. | SUPERIOR G1T38 DOSING SCHEMES |
| TW202114689A (zh) * | 2019-08-06 | 2021-04-16 | 大陸商江蘇恒瑞醫藥股份有限公司 | Cdk4/6抑制劑與多靶點酪胺酸激酶抑制劑聯合在製備治療腫瘤的藥物中的用途 |
| EP4041399A1 (en) | 2019-10-02 | 2022-08-17 | Tolremo Therapeutics AG | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer |
| US20210369709A1 (en) * | 2020-05-27 | 2021-12-02 | Astrazeneca Ab | EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER |
| KR20230028798A (ko) | 2020-06-25 | 2023-03-02 | 톨레모 테라퓨틱스 아게 | 암 치료를 위한 CBP/p300 브로모도메인 억제제 및 KRAS 억제제의 조합물 |
| BR112022025911A2 (pt) * | 2020-06-25 | 2023-01-10 | Tolremo Therapeutics Ag | Combinação de um inibidor de bromodomínio de cbp/p300 e um inibidor de egfr para uso no tratamento de um cpcnp com egfr mutante |
| IL307402A (en) | 2021-04-07 | 2023-12-01 | Tolremo Therapeutics Ag | The tercyclic derivatives, pharmaceutical compounds and their use in the treatment or amelioration of cancer |
| CN113628682B (zh) * | 2021-08-11 | 2023-10-24 | 上海小海龟科技有限公司 | 一种t790m和c797s顺反式突变类型识别及计算方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2522346T3 (es) | 2008-08-22 | 2014-11-14 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de CDK |
| JO3300B1 (ar) | 2012-06-06 | 2018-09-16 | Novartis Ag | مركبات وتركيبات لتعديل نشاط egfr |
| CN105828822B (zh) * | 2013-08-14 | 2019-10-18 | 诺华股份有限公司 | 用于治疗癌症的组合疗法 |
| EP3340990B1 (en) * | 2015-08-28 | 2019-09-25 | Novartis AG | Pharmaceutical combinations comprising (a) the cyclin dependent kinase 4/6 (cdk4/6) inhibitor lee011 (=ribociclib), and (b) the epidermal growth factor receptor (egfr) inhibitor erlotinib, for the treatment or prevention of cancer |
| EP3585389A4 (en) * | 2017-02-22 | 2020-12-23 | G1 Therapeutics, Inc. | EGFR-CAUSED CANCER TREATMENT WITH LESS SIDE EFFECTS |
-
2018
- 2018-08-01 US US16/632,954 patent/US20200155566A1/en not_active Abandoned
- 2018-08-01 CN CN201880050149.7A patent/CN110996962A/zh active Pending
- 2018-08-01 KR KR1020207004657A patent/KR20200036879A/ko not_active Withdrawn
- 2018-08-01 AU AU2018311522A patent/AU2018311522A1/en not_active Abandoned
- 2018-08-01 BR BR112020001821-0A patent/BR112020001821A2/pt not_active Application Discontinuation
- 2018-08-01 WO PCT/IB2018/055791 patent/WO2019026006A1/en not_active Ceased
- 2018-08-01 MX MX2020001253A patent/MX2020001253A/es unknown
- 2018-08-01 EP EP18760055.6A patent/EP3661519A1/en not_active Withdrawn
- 2018-08-01 CA CA3069561A patent/CA3069561A1/en not_active Abandoned
- 2018-08-01 SG SG11201913244QA patent/SG11201913244QA/en unknown
- 2018-08-01 JP JP2020505467A patent/JP2020529423A/ja active Pending
- 2018-08-01 RU RU2020108191A patent/RU2020108191A/ru not_active Application Discontinuation
- 2018-08-03 TW TW107127152A patent/TW201909921A/zh unknown
-
2020
- 2020-01-14 PH PH12020500099A patent/PH12020500099A1/en unknown
- 2020-01-28 JO JOP/2020/0015A patent/JOP20200015A1/ar unknown
- 2020-01-30 CL CL2020000271A patent/CL2020000271A1/es unknown
- 2020-01-30 IL IL272369A patent/IL272369A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN110996962A (zh) | 2020-04-10 |
| JP2020529423A (ja) | 2020-10-08 |
| JOP20200015A1 (ar) | 2020-01-28 |
| BR112020001821A2 (pt) | 2020-07-21 |
| RU2020108191A (ru) | 2021-09-03 |
| MX2020001253A (es) | 2020-07-13 |
| TW201909921A (zh) | 2019-03-16 |
| SG11201913244QA (en) | 2020-02-27 |
| AU2018311522A1 (en) | 2020-01-16 |
| US20200155566A1 (en) | 2020-05-21 |
| IL272369A (en) | 2020-03-31 |
| WO2019026006A1 (en) | 2019-02-07 |
| PH12020500099A1 (en) | 2020-09-14 |
| CA3069561A1 (en) | 2019-02-07 |
| EP3661519A1 (en) | 2020-06-10 |
| KR20200036879A (ko) | 2020-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020000271A1 (es) | Combinación terapéutica de un inhibidor tirosina quinasa del egfr y un inhibidor de quinasa dependiente de ciclina. | |
| CL2020000270A1 (es) | Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf. | |
| CL2021001292A1 (es) | Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres | |
| CL2019003091A1 (es) | Terapia de combinación. | |
| MX2021004639A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
| EA201892395A1 (ru) | Лекарственные составы ингибитора lsd1 | |
| AR101504A1 (es) | Combinaciones terapéuticas de un inhibidor de la btk, un inhibidor de la pi3k, un inhibidor de la jak-2, y/o un inhibidor de la cdk4/6 | |
| CO2019009722A2 (es) | Dendrímeros terapéuticos | |
| CO2017012381A2 (es) | Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue | |
| MX2017000628A (es) | Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia. | |
| MX2018016330A (es) | Combinaciones para tratamiento del cáncer. | |
| MX2016015434A (es) | Combinaciones farmaceuticas para tratar cancer. | |
| MX2017012123A (es) | Combinaciones de un compuesto inhibidor de fosfoinositido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cancer. | |
| DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
| MX393601B (es) | Uso del inhibidor mejorador de homologo zeste 2 (ezh2) combinado con el inhibidor tirosina cinasa de bruton (btk) en la preparacion de farmacos para tratar tumores. | |
| MX2020012058A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cancer. | |
| MX2022005985A (es) | Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo. | |
| MX2021010041A (es) | Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt. | |
| CL2021003032A1 (es) | Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton | |
| CL2021001623A1 (es) | Terapia de combinación con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cáncer | |
| ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
| CO2024009144A2 (es) | Inhibidores de cinasa met | |
| MX387726B (es) | Derivados de ftalazina como inhibidores de parp1, parp2 y/o tubulina útiles para el tratamiento del cáncer. | |
| JOP20250311A1 (ar) | مثبطات tyk2 وتركيبات وطرق لها | |
| ECSP16086232A (es) | (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina |